Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
This study aims to test whether CD271, which is a stem cell marker in hypopharyngeal cancer, is a good target in therapy. A humanized anti-CD271 antibody was developed. The antibody possessed antibody-dependent cellular cytotoxicity capacity against cancer cells in vitro. Antibody administration in mice bearing human cancer cells led to tumor volume suppression. CD271-positive cancer cells in the antibody-treated mice decreased. Collectively, the CD271 antibody treatment for hypopharyngeal cancer is a promising therapy.
|